Mouse pre-microRNA Expression Construct mir-215
- Known as:
- Mouse pre-microRNA Expression Construct mir-215
- Catalog number:
- mmir-215-pa-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- Mouse pre-microRNA Expression Construct mir-215
Related genes to: Mouse pre-microRNA Expression Construct mir-215
- Gene:
- MIR215 NIH gene
- Name:
- microRNA 215
- Previous symbol:
- MIRN215
- Synonyms:
- hsa-mir-215
- Chromosome:
- 1q41
- Locus Type:
- RNA, micro
- Date approved:
- 2004-04-23
- Date modifiied:
- 2019-01-18
Related products to: Mouse pre-microRNA Expression Construct mir-215
Related articles to: Mouse pre-microRNA Expression Construct mir-215
- Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that western blot data shown in Fig. 1C on p. 1232 were strikingly similar to data in a paper that had previously been published in the journal that was written by different authors at different research institutes. Upon performing an independent analysis of the data in this paper in the Editorial Office, it also came to light that the cellular images featured in Fig. 6B on p. 1233 had also previously appeared in another article published in the journal that was similarly written by different authors at different research institutes. Given that the abovementioned data had already been published before the receipt of this paper at , the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Molecular Medicine 42:1229‑1236, 2018; DOI: 10.3892/ijmm.2018.3703]. - Source: PubMed
Publication date: 2026/06/05
Gao XiaoxuCai YanAn Ruifang - Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Despite significant advances in screening and treatment, the prognosis for advanced-stage disease continues to be poor. One thriving area of research focuses on the use of epigenetic alterations for the diagnosis, prediction of treatment response, and prognosis of CRC. In this study, we evaluated original studies and meta-analyses published within the past five years to identify the most clinically relevant epigenetic biomarkers. DNA methylation-based assays, particularly those targeting and in stool and plasma, exhibit superior diagnostic accuracy compared to other epigenetic modalities. Circulating microRNAs (miRNAs), including miR-211, miR-197, and miR-21, as well as specific long non-coding RNAs (lncRNAs) such as SNHG14, LINC01485, and ASB16-AS1, also show promising diagnostic potential. Furthermore, panels combining multiple epigenetic markers, especially those incorporating DNA methylation targets, have demonstrated improved sensitivity and specificity for early-stage CRC detection. In the context of therapeutic prediction, microRNAs such as miR-140, miR-21, and miR-4442 have been associated with chemotherapy resistance and recurrence risk. DNA methylation markers like , and have also shown predictive value, while lncRNAs including MALAT1 and GAS6-AS1 remain less validated. Regarding prognosis, miRNAs appear to be the most promising biomarkers, with miR-675-5p and miR-150 being associated with poor survival, while miR-767-5p and miR-215 predict favorable outcomes. Methylation of , , and has been identified as an independent negative prognostic factor, while hypermethylation is linked to better prognosis. Selected lncRNAs, including THOR and LINC01094, have also demonstrated significant prognostic value. Despite these advances, challenges persist, including inconsistent reporting, limited external validation, and a lack of replication by independent research groups. - Source: PubMed
Publication date: 2025/08/12
Chilimoniuk ZuzannaGładysz KonradMoniczewska NataliaChawrylak KatarzynaPelc ZuzannaMlak Radosław - Diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease (ESKD) globally. Despite advances in our understanding of its pathophysiology, current therapies are often insufficient to stop its progression. In recent years, microRNAs (miRNAs)-small, non-coding RNA molecules involved in post-transcriptional gene regulation-have emerged as critical modulators of key pathogenic mechanisms in DKD, including fibrosis, inflammation, oxidative stress, and apoptosis. Numerous studies have identified specific miRNAs that either exacerbate or mitigate renal injury in DKD. Among them, miR-21, miR-192, miR-155, and miR-34a are associated with disease progression, while miR-126-3p, miR-29, miR-146a, and miR-215 demonstrate protective effects. These molecules are also detectable in plasma, urine, and renal tissue, making them attractive candidates for diagnostic and prognostic biomarkers. Advances in therapeutic technologies such as antagomiRs, mimics, locked nucleic acids, and nanoparticle-based delivery systems have opened new possibilities for targeting miRNAs in DKD. Additionally, conventional drugs, including SGLT2 inhibitors, metformin, and GLP-1 receptor agonists, as well as dietary compounds like polyphenols and sulforaphane, may exert nephroprotective effects by modulating miRNA expression. Recent evidence also highlights the role of gut microbiota in regulating miRNA activity, linking metabolic and immune pathways relevant to DKD progression. Further research is needed to define stage-specific miRNA signatures, improve delivery systems, and develop personalized therapeutic approaches. Modulation of miRNA expression represents a promising strategy to slow DKD progression and improve patient outcomes. - Source: PubMed
Publication date: 2025/07/11
Rodzoń-Norwicz MałgorzataKogut PatrykSowa-Kućma MagdalenaGala-Błądzińska Agnieszka - - Source: PubMed
- Emerging evidence highlights the therapeutic potential of microRNAs (miRNAs) in cancer, positioning them as key molecular tools in personalized medicine. In this study, we aim to identify miRNAs as novel indicators of poor prognosis in Triple Negative Breast Cancer (TNBC) patients and to explore their potential therapeutic options for TNBC. - Source: PubMed
Publication date: 2025/06/01
Unnikrishnan KavithaKrishnankutty Chandrika SivakumarRam Kumar Ram MohanSrinivas Priya